Literature DB >> 25828295

The TUDCA trial--innovative trial designs for amyotrophic lateral sclerosis drugs?

A C Ludolph1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25828295     DOI： 10.1111/ene.12691

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  3 in total

1.  Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy.

Authors:  Nathalie Launay; Montserrat Ruiz; Laia Grau; Francisco J Ortega; Ekaterina V Ilieva; Juan José Martínez; Elena Galea; Isidre Ferrer; Erwin Knecht; Aurora Pujol; Stéphane Fourcade
Journal:  Acta Neuropathol       Date:  2016-12-21       Impact factor: 17.088

2.  Tauroursodeoxycholic Acid (TUDCA)-Lipid Interactions and Antioxidant Properties of TUDCA Studied in Model of Photoreceptor Membranes.

Authors:  Michał J Sabat; Anna M Wiśniewska-Becker; Michał Markiewicz; Katarzyna M Marzec; Jakub Dybas; Justyna Furso; Paweł Pabisz; Mariusz Duda; Anna M Pawlak
Journal:  Membranes (Basel)       Date:  2021-04-29

Review 3.  Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives.

Authors:  Magdalena Kusaczuk
Journal:  Cells       Date:  2019-11-20       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.